Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373786 · ClinicalTrials.gov registry record · Phase 1
A Study of RG-012 in Subjects With Alport Syndrome
A Phase 1 study of Alport Syndrome, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 7
- Study locations
NCT03373786: Completed Phase 1 study of Alport Syndrome, sponsored by Genzyme, a Sanofi Company.
NCT03373786 is a Phase 1 study of Alport Syndrome that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 4 participants, below the 618-participant average among 5 other Alport Syndrome trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373786, a Phase 1 study of Alport Syndrome, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
Primary Outcome
Incidence and severity of adverse events
Conditions Studied
Interventions
- DRUG RG012
Study Locations (7)
California
- eStudySite - La Mesa
- Academic Medical Research Institute - Los Angeles
- Apex Research of Riverside - Riverside
Florida
- Eminence Medical & Clinical Research - Tampa
Texas
- Houston Nephrology Research - Cypress
Utah
- Utah Kidney Research Institute - Salt Lake City
Wisconsin
- Allegiance Research Specialists, LLC - Wauwatosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2019-05-20 |
| Phase | Phase 1 |
What the finished NCT03373786 record still lists
NCT03373786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 618-participant average among 5 other Alport Syndrome trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alport Syndrome appearing as the primary indexed condition, and to 1 intervention - of which RG012 is the first listed.
NCT03373786 lists 7 locations in 5 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT03373786 about?
NCT03373786 is a clinical study titled "A Study of RG-012 in Subjects With Alport Syndrome". This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
What is the current status of trial NCT03373786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-12-22. Estimated completion is 2019-05-20.
What conditions does trial NCT03373786 study?
This clinical trial studies the following conditions: Alport Syndrome.
What interventions are being tested in trial NCT03373786?
The interventions under investigation include: RG012 (DRUG).
Who is sponsoring clinical trial NCT03373786?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373786 being conducted?
This trial has 7 study locations across California, Florida, Texas, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alport Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
NEPTUNE Match Study
RECRUITING · NA
-
ASF Alport Patient Registry
RECRUITING
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI